Results 171 to 180 of about 127,260 (361)

The Demographics and Outcomes of Women With Stage II Endometrial Cancer Diagnosed in Australia 2005–2007

open access: yesAustralian and New Zealand Journal of Obstetrics and Gynaecology, EarlyView.
ABSTRACT Background Stage II endometrial cancer comprises 5% to 10% of cases and is pathologically diverse. Retrospective data guides recommendations which suggest surgical staging with adjuvant therapy, but the role of radical surgery and lymphadenectomy is uncertain, due to conflicting outcomes.
Jonathan Sandeford   +2 more
wiley   +1 more source

Endometrial Carcinoma Metastatic to the Clitoris: A Case Report and Review of the Literature

open access: yesActa Medica Iranica, 2013
Endometrial cancer generally carries a good prognosis. Endometrial carcinoma more frequently metastasizes to the pelvic and para-aortic nodes. Visceral metastases usually occur in the vagina and ovaries.
Fereshteh Fakor   +2 more
doaj  

A study of oral metformin for the intravesical treatment of non‐muscle‐invasive bladder cancer

open access: yesBJU International, EarlyView.
Objectives To evaluate the effect of metformin on non‐muscle‐invasive bladder cancer (NMIBC) marker lesions. Patients and methods A phase II, open‐label, multicentre, marker lesion trial using oral metformin in patients with primary or recurrent, multiple, low‐grade Ta‐T1 NMIBC was conducted. After transurethral resection for histological confirmation,
Jons W. van Hattum   +12 more
wiley   +1 more source

Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of transvaginal sonography vs MR imaging. [PDF]

open access: green, 1993
A DelMaschio   +6 more
openalex   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma [PDF]

open access: bronze, 1990
Hironobu Sasano   +3 more
openalex   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Renal Cell Carcinoma subtyping: learning from multi-resolution localization [PDF]

open access: yesarXiv
Renal Cell Carcinoma is typically asymptomatic at the early stages for many patients. This leads to a late diagnosis of the tumor, where the curability likelihood is lower, and makes the mortality rate of Renal Cell Carcinoma high, with respect to its incidence rate.
arxiv  

Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer [PDF]

open access: bronze, 1991
Carlo Pesce   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy